Business Wire

Vertex Announces Long-Term Access Agreement in Sweden for Cystic Fibrosis Medicine ORKAMBI® (lumacaftor/ivacaftor)

Jaa

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that ORKAMBI® (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF) in people with two copies of the F508del mutation, ages six and older, will be reimbursed in Sweden after concluding the three-party negotiations with TLV and the county councils. Reimbursement is effective from July 1. The innovative, long-term access agreement also provides a framework for the assessment and access of our future CF medicines.

“We are delighted that people with CF in Sweden will join the thousands of others around the world who are already benefitting from our CF medicines,” said Simon Bedson, International General Manager at Vertex. “We commend the Swedish authorities for partnering with us on an innovative, long-term access agreement. In countries where Vertex remains actively involved in reimbursement discussions, we encourage these health authorities and governments to match the commitment to innovation shown in Sweden to secure access for all patients who may benefit.”

CF is a devastating rare disease that causes continuous damage to multiple organs from birth. In the lungs, a build-up of sticky mucus causes progressive and permanent damage, severe infections and ultimately premature death. In addition to Sweden, countries where lumacaftor/ivacaftor is available to all eligible patients include Austria, Germany, Ireland, Italy, the Netherlands and the U.S.

About Cystic Fibrosis

Cystic fibrosis is a rare, life-shortening genetic disease affecting approximately 75,000 people in North America, Europe and Australia.

CF is caused by a defective or missing CFTR protein resulting from mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF. There are approximately 2,000 known mutations in the CFTR gene. Some of these mutations, which can be determined by a genetic test, or genotyping test, lead to CF by creating non-working or too few CFTR proteins at the cell surface. The defective function or absence of CFTR protein results in poor flow of salt and water into and out of the cell in a number of organs. In the lungs, this leads to the build-up of abnormally thick, sticky mucus that can cause chronic lung infections and progressive lung damage in many patients that eventually leads to death. The median age of death is in the mid-to-late 20s.

About ORKAMBI ® (lumacaftor/ivacaftor) and the F508del mutation

In people with two copies of the F508del mutation, the CFTR protein is not processed and trafficked normally within the cell, resulting in little-to-no CFTR protein at the cell surface. Patients with two copies of the F508del mutation are easily identified by a simple genetic test.

ORKAMBI is a combination of lumacaftor, which is designed to increase the amount of mature protein at the cell surface by targeting the processing and trafficking defect of the F508del-CFTR protein, and ivacaftor, which is designed to enhance the function of the CFTR protein once it reaches the cell surface. Lumacaftor/ivacaftor is available as tablets and is typically taken twice per day.

For complete product information, please see the Summary of Product Characteristics that can be found on www.ema.europa.eu.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.

Founded in 1989 in Cambridge, Mass., Vertex's headquarters is now located in Boston's Innovation District. Today, the company has research and development sites and commercial offices in the United States, Europe, Canada and Australia. Vertex is consistently recognized as one of the industry's top places to work, including being named to Science magazine's Top Employers in the life sciences ranking for eight years in a row.

For additional information and the latest updates from the company, please visit www.vrtx.com.

(VRTX-GEN)

Contact information

Vertex Pharmaceuticals Incorporated
Investors:
Michael Partridge, + 1-617-341-6108
or
Eric Rojas, + 1-617-961-7205
or
Zach Barber, + 1-617-341-6470
or
Media:
mediainfo@vrtx.com
or
North America:
Heather Nichols, + 1-617-341-6992
or
Europe & Australia:
Marie von Seyfried, + 447933 500887
or
Rob Clark, + 447736 473227

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

BCW Names Jillian Janaczek New York Market Leader19.9.2018 18:50Tiedote

BCW (Burson Cohn & Wolfe), a leading global communications agency, today announced Jillian Janaczek has been named Executive Vice President, Managing Director, Market Leader for New York, the firm’s largest market globally. In her new role, she will manage talent and operations of the firm’s headquarters office, maintain key client relationships and help drive business growth across all industry sectors. Rachi Govil will assume the role of Executive Vice President, Managing Director, New York Healthcare Practice Leader. “Jillian is a veteran communications professional and leader with deep experience running and growing multimillion dollar clients and large teams,” said Chris Foster, President, North America, BCW, to whom Janaczek will report. “She is also deeply committed to finding and nurturing the best talent in the business. Jillian will be an invaluable partner to me and to our entire organization as she builds the business in our largest market.” Before this role, Janaczek spent

District Court in Rotterdam (Netherlands), Accepts Jurisdiction in Securities Fraud Litigation against Petrobras19.9.2018 18:11Tiedote

On January 23, 2017, Stichting Petrobras Compensation Foundation (the “Foundation”) initiated an international collective action for Petrobras investors who purchased Petrobras securities outside of the United States and have suffered damages as a consequence of fraud that was uncovered by the “Lavo Jato” or “Operation Car Wash” investigations at the Brazilian petrochemical company that was once the 5th largest company in the world. Petrobras has structured a significant part of its assets through the Netherlands and one of the entities issuing Petrobras securities (Petrobras Global Finance B.V.) is based in Rotterdam, the Netherlands. Moreover Petrobras is benefiting from the Dutch tax environment and Dutch investment protection treaties. Despite its strong nexus with the Dutch jurisdiction, Petrobras strongly contested the jurisdiction of the District Court in Rotterdam. Today the District Court in Rotterdam ruled in favor of the Foundation by accepting jurisdiction. Also the Court r

TRAXENS Digital Freight Train Honored as « Coup De Cœur » By ERCI Innovation Awards IoT Based Solution Presented At InnoTrans 201819.9.2018 17:00Tiedote

TRAXENS today announced that ERCI Eurail Clusters has named TRAXENS DIGITAL FREIGHT TRAIN, Europe's first Freight Train to use an innovative IoT-based system allowing digitalization of operations, the winner of their « Coup de Cœur » Innovation Award. The prize has been given to the company at the InnoTrans 2018 tradeshow in Berlin. Initially launched with Fret SNCF, the TRAXENS DIGITAL FREIGHT TRAIN solution is based on smart devices capable of communicating with each other using wireless digital network. TRAXENS solution goes beyond smart wagons to connect the entire train offering new high-value-added services. Inherited from the Shipping Industry, TRAXENS DIGITAL FREIGHT TRAIN has been designed to work worldwide and manage any type of asset (e.g., Dry or Reefer container, wagon, trailer) which means that rail freight can be connected to the rest of the supplier chain anywhere, to explore and leverage door-to-door multimodal applications. « This industry recognition is a major miles

WilsonHCG Recognized as a Top Global RPO Provider in HRO Today Baker's Dozen for Eighth Year in a Row19.9.2018 17:00Tiedote

WilsonHCG, a multi-award winning global leader in innovative talent solutions, has once again been recognized in HRO Today magazine's annual RPO Baker's Dozen list. It’s the eighth year in a row the company has been honored for its exemplary partnership with its clients. WilsonHCG was one of only two providers to see an increase in client satisfaction scores. The Baker’s Dozen highlights the top recruitment process outsourcing (RPO) providers on a global level and is based solely on feedback from buyers. It’s one of the most distinguished customer satisfaction surveys in the RPO industry and service providers are rated on a variety of factors including size-of-deal, breadth of solutions, and quality of service. “We’re extremely proud to be ranked in the Baker’s Dozen for the eighth year in a row. It showcases WilsonHCG’s commitment to clients and is a testament to the effort that each and every one of our people put in on a daily basis,” says John Wilson, CEO at WilsonHCG. “We’re thank

Sharjah Announces its First Fully Integrated Investors Services Centre19.9.2018 16:36Tiedote

In a bid to support prospective foreign investors expand their international growth ambition in the UAE, its third largest emirate, Sharjah, has announced the launch of a digitally robust business facilitation initiative, the Investors Services Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180919005444/en/ General photo of Sharjah (Photo: Shurooq) The emirate’s investment and development authority, Shurooq, has partnered with Injazat Services, to develop this high-end facility to offer an exhaustive list of fully integrated business consultancy services, which will specially benefit new players on the UAE turf. The office will serve as a key access point for global business owners and investors in Sharjah, and serviced by a highly trained staff, will play an integral role in facilitating high-level and mid-level investments across a variety of sectors within the emirate. Through this service centre, investors will b

ISACA Research: Only 4 in 10 Tech Professionals Confident in Security of Their Organizations’ AI Deployments19.9.2018 16:00Tiedote

Despite heightened interest in enterprise deployment of artificial intelligence, only 40 percent of respondents to ISACA’s second annual Digital Transformation Barometer express confidence that their organizations can accurately assess the security of systems based on AI and machine learning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180919005423/en/ ISACA's 2018 Digital Transformation Barometer looks at companies' digital transformation journeys, including the technologies with the biggest impacts and the positive effect of digitally literate leaders. (Graphic: Business Wire) This becomes especially striking given the potential for serious consequences from maliciously trained AI; survey respondents identify social engineering, manipulated media content and data poisoning as the types of malicious AI attacks that pose the greatest threat within the next five years. AI/machine learning also continued to rise toward the

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme